By the age of 95, individuals who die with and without dementia exhibit a similar burden of neuropathological changes.58 Hence, a positive plasma p-tau should not be used as a standalone diagnostic test for AD but must be interpreted within a clinical context.59 A diagnosis must benefit the patient and biomarker analysis should only be conducted when there is a reasonable suspicion of AD. This evidence concerns the gene MAPT and Alzheimer disease.